Improvement of neurocognitive function in responders to an antiviral therapy for chronic hepatitis C

Hepatology

Volumn 58, Issue 2, 2013, Pages 497-504

  Kraus, Michael R ^a,b   Schäfer, Arne ^a   Teuber, Gerlinde ^c   Porst, Heiner ^d   Sprinzl, Kathrin ^c   Wollschläger, Sven ^d   Keicher, Christian ^a   Scheurlen, Michael ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b Abteilung Gynäkologie und Geburtshilfe   (Germany)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^d ACADEMIC TEACHING HOSPITAL DRESDEN FRIEDRICHSTADT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ALERTNESS; ANTIVIRAL THERAPY; ARTICLE; ATTENTION; COGNITION; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; DRUG RESPONSE; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MENTAL PERFORMANCE; MULTICENTER STUDY; PRIORITY JOURNAL; VIRAL CLEARANCE; VIRUS LOAD; WORKING MEMORY;

ADULT; ANTIVIRAL AGENTS; ATTENTION; COGNITION; COGNITION DISORDERS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GERMANY; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PSYCHOLOGICAL TESTS; PSYCHOMETRICS; RECOMBINANT PROTEINS; REPRODUCIBILITY OF RESULTS; RIBAVIRIN; TREATMENT OUTCOME;

EID: 84881027564     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26229     Document Type: Article

References (34)

1. Global burden of disease (GBD) for hepatitis C.J Clin Pharmacol 2004;44:20-29.
2. World Health Organization Initiative for Vaccine Research. Hepatitis C. (Accessed July 16, 2009, at http://www.who.int/vaccine_research/diseases/viral_cancers/en/index2.html).
3. Thomas DL, Seeff LB.Natural history of hepatitis C.Clin Liver Dis 2005;9:383-398, vi.
4. Fattovich G, Stroffolini T, Zagni I, Donato F.Hepatocellular carcinoma in cirrhosis: incidence and risk factors.Gastroenterology 2004;127:S35-50.
5. Di Bisceglie AM, Lyra AC, Schwartz M, Reddy RK, Martin P, Gores G, et al.Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status.Am J Gastroenterol 2003;98:2060-2063.
6. Organ Procurement and Transplantation Network. US liver transplants performed: January 1, 1988 to April 30, 2008. (Accessed July 16, 2009, at http://www.optn.org).
7. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ.The prevalence of hepatitis C virus infection in the United States, 1999 through 2002.Ann Intern Med 2006;144:705-714.
8. Wasley A, Alter MJ.Epidemiology of hepatitis C: geographic differences and temporal trends.Semin Liver Dis 2000;20:1-16.
9. Hoofnagle JH, Seeff LB.Peginterferon and ribavirin for chronic hepatitis C.N Engl J Med 2006;355:2444-2451.
10. Kraus MR, Schafer A, Wissmann S, Reimer P, Scheurlen M.Neurocognitive changes in patients with hepatitis C receiving interferon alfa-2b and ribavirin.Clin Pharmacol Ther 2005;77:90-100.
11. Reichenberg A, Gorman JM, Dieterich DT.Interferon-induced depression and cognitive impairment in hepatitis C virus patients: a 72 week prospective study.Aids 2005;19( Suppl 3):S174-178.
12. Byrnes V, Miller A, Lowry D, Hill E, Weinstein C, Alsop D, et al.Effects of anti-viral therapy and HCV clearance on cerebral metabolism and cognition.J Hepatol 2012;56:549-556.
13. Pattullo V, McAndrews MP, Damyanovich A, Heathcote EJ.Influence of hepatitis C virus on neurocognitive function in patients free from other risk factors: validation from therapeutic outcomes.Liver Int 2011;31:1028-1038.
14. Sarrazin C, Berg T, Ross RS, Schirmacher P, Wedemeyer H, Neumann U, et al.[Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection.]Z Gastroenterol 2010;48:289-351.
15. Zeuzem S, Berg T, Moeller B, Hinrichsen H, Mauss S, Wedemeyer H, et al.Expert opinion on the treatment of patients with chronic hepatitis C.J Viral Hepat 2009;16:75-90.
16. Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J, et al.Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia.J Hepatol 2006;44:97-103.
17. PEG-Intron product label, Schering-Plough 2005. Available at: http://www.spifiles.com/pipeg-intron.pdf.
18. Pegasys product label, Roche 2005. Available at: http://www.rocheusa.com/products/pegasys.
19. Zimmermann P, Fimm B.Testbatterie zur Aufmerksamkeitsprüfung (TAP) - Test for Attentional Performance. Version 1.02c.Herzogenrath:Psytest, 1994.
20. Zimmermann P, Fimm B. A test battery for attentional performance. In: Leclercq M, Zimmermann P, eds.Applied Neuropsychology of Attention.London:Psychology Press, 2002.
21. SPSS. SPSS for Windows Release 15.0.1.Chicago:SPSS Inc.;2006.
22. Wobrock T, Mihm U, Lohr C, Hofmann WP, Sarrazin C, Zeuzem S, et al.Cognition in hepatitis C patients treated with pegylated interferon.World J Biol Psychiatry 2009;10:819-826.
23. Forton DM, Allsop JM, Main J, Foster GR, Thomas HC, Taylor-Robinson SD.Evidence for a cerebral effect of the hepatitis C virus.Lancet 2001;358:38-39.
24. Forton DM, Allsop JM, Cox IJ, Hamilton G, Wesnes K, Thomas HC, et al.A review of cognitive impairment and cerebral metabolite abnormalities in patients with hepatitis C infection.Aids 2005;19( Suppl 3):S53-S63.
25. Forton DM, Taylor-Robinson SD, Thomas HC.Central nervous system changes in hepatitis C virus infection.Eur J Gastroenterol Hepatol 2006;18:333-338.
26. Weissenborn K, Tryc AB, Heeren M, Worthmann H, Pflugrad H, Berding G, et al.Hepatitis C virus infection and the brain.Metab Brain Dis 2009;24:197-210.
27. Hilsabeck RC, Perry W, Hassanein TI.Neuropsychological impairment in patients with chronic hepatitis C.Hepatology 2002;35:440-446.
28. Forton DM, Thomas HC, Murphy CA, Allsop JM, Foster GR, Main J, et al.Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease.Hepatology 2002;35:433-439.
29. McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, et al.Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.Gastroenterology 2002;123:1061-1069.
30. Foster GR, Goldin RD, Thomas HC.Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis.Hepatology 1998;27:209-212.
31. Foster GR.Quality of life considerations for patients with chronic hepatitis C.J Viral Hepat 2009;16:605-611.
32. Arnaud N, Dabo S, Maillard P, Budkowska A, Kalliampakou KI, Mavromara P, et al.Hepatitis C virus controls interferon production through PKR activation.PloS One 2010;5:e10575.
33. Pfeffer LM, Madey MA, Riely CA, Fleckenstein JF.The induction of type I interferon production in hepatitis C-infected patients.J Interferon Cytokine Research 2009;29:299-306.
34. Hilsabeck RC, Hassanein TI, Ziegler EA, Carlson MD, Perry W.Effect of interferon-alpha on cognitive functioning in patients with chronic hepatitis C.J Int Neuropsychol Soc 2005;11:16-22.